Founded in 2019 with the goal of revolutionizing biomarker research.
Our Mission
To generate new applications utilizing MALDI Mass Spectrometry Imaging to study changes in the glycosylation of various disease states. By generating streamlined methods with proven clinical impact, we hope to introduce accurate simplified assays to improve patient care and treatment.
“Glycopath is utilizing a rapidly growing field of knowledge and sophisticated instrumentation to create innovative solutions to roadblocks in biomarker discovery and clinical assay development”
GlycoTyper technology
The proprietary GlycoTyper is designed to classify how the glycans, or sugar code on proteins, change during the development of cancer, metabolic diseases and aging. For decades, the role of glycans and glycoproteins have been evaluated in various disease states. Through extensive studies focused on elucidating the biological functions of glycosylation, researchers have been able to implicate alterations in these functions to tumor formation, metastasis, and immune response.
Although this has been studied for many years, the relevance of these studies has been limited due to a lack of clinical assays. The GlycoTyper assay was developed to directly address the need for a more high-throughput method for protein-specific glycan analysis from biological samples.
Our glycan profiling technology captures glycoproteins from blood using antibodies. These captured proteins then undergo direct glycan analysis using MALDI mass spectrometry.
“GlycoTyper is proving to be an applicable assay for stratifying patients with other diseases besides cancer and liver disease. Our unique assay strategy is highly reproducible and robust, presenting a strong foundation for additional clinical assays targeting disease-associated changes in glycosylation.”
What We've Achieved
Successful application of GlycoTyper method to Lyme Disease with publication of “Lyme Disease IgG N-linked Glycans Contrast the Canonical Inflammatory Signature”
Recipient of SCRA Federal Matching Grant
Recipient of a Phase I STTR grant for the project titled: “Development of the GlycoHCCTyper for the early detection of HCC”
Publication of “GlycoFibroTyper: A Novel Method for the Glycan Analysis of IgG and the Development of a Biomarker Signature of Liver Fibrosis”
Successful launch of Basic N-Glycan Kits
Recipient of a Phase I STTR grant for the project titled: “Development of the GlycoFibrotyper for Detection of Liver Fibrosis”
Successful implementation of a method published in Current Protocols by Alyson Black, et. al.
Support of well renowned researchers from across the globe
Collaboration with Bruker Daltonics